Non-Alcoholic Fatty Liver Disease Drug Target Uncovered

Mount Sinai Institute for Liver Research Established to Advance Understanding and Treatment of Liver Disease Amid Global Concerns

Potential New Targets Identified in Advanced Non-Alcoholic Fatty Liver Disease

Cutting-edge cancer and COVID-19 approaches could reduce organ scarring

"InSphero Launches Industry's First Automation-compatible 3D Human Liver Disease Platform for NASH Drug Discovery and Screening"

"MDR Infections Surge In Cirrhosis" - Zeena Nackerdien

"Liver Cancer Death Rate In US Surged 43 Percent In 16 Years" - Maddie Bender

Mount Sinai Researchers Highlight New Mechanisms and Therapeutic Strategies for Non-Alcoholic Fatty Liver Disease in Nature Medicine

"Aramchol Resolves NASH Without Worsening Of Fibrosis In Phase 2b Study" - Talitha Bennett